Compare Amplitude Inc (AMPL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplitude Inc vs Novo Nordisk A/S — how do they compare? Amplitude Inc trades at $12.42 (market cap $1.59B), while Novo Nordisk A/S trades at $46.02 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 130.7× Amplitude Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Amplitude Inc pays none. Which is the better fit depends on your goals.
| AMPL | NVO | |
|---|---|---|
Market Cap | $1.59B | $207.85B |
Sector | Technology | Health |
52-Week High | $12.69 | $63.98 |
52-Week Low | $5.61 | $35.29 |
Enterprise Value | $1.45B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amplitude (AMPL) trades at $12.19, up 8.26% over 24 hours, with strong technical momentum indicated by bullish moving averages. The company shows robust revenue growth, reaching $343.21 million in 2025, but continues to report net losses with a -26.59% margin. Recent news highlights AI-driven growth initiatives and enterprise customer expansion as key catalysts.
While analyst consensus remains bullish with 67% buy ratings and a $12.08 price target, persistent profitability challenges and ongoing legal investigations present significant risks. The stock's current valuation at 4.49x sales appears reasonable given growth prospects, but sustained losses require careful monitoring of margin improvement efforts.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
